Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPHENE 65 vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Relief of mild to moderate pain,FDA-approved for pain management (withdrawn due to cardiac toxicity)
Mild to moderate pain,Fever
Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life of propoxyphene: 6-12 hours (mean ~8 hours); norpropoxyphene half-life: 22-36 hours, leading to accumulation with chronic dosing. Clinical context: prolonged half-life in elderly and hepatic impairment increases risk of toxicity.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Hepatic via CYP3A4 and CYP2D6 to norpropoxyphene (active metabolite with longer half-life). Minor metabolism via N-demethylation and glucuronidation.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal elimination of unchanged drug and metabolites: propoxyphene and its major metabolite norpropoxyphene account for ~20-30% as unchanged drug in urine; remainder as conjugated metabolites. Biliary/fecal elimination accounts for <10%.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Propoxyphene: ~78% bound to albumin; norpropoxyphene: ~95% bound to albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Volume of distribution: 16-20 L/kg (suggesting extensive tissue binding). Clinical meaning: high Vd indicates wide distribution into tissues, contributing to long half-life and potential for accumulation.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: approximately 30-70% (first-pass metabolism). Other routes: not formulated for parenteral use.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl < 30 m L/min: Avoid use due to accumulation of toxic metabolite norpropoxyphene. Cr Cl 30-50 m L/min: Reduce dose to 50 mg every 6 hours.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh Class C: Contraindicated. Child-Pugh Class B: Avoid use or reduce dose by 50% with close monitoring.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not recommended for use in pediatric patients due to risk of respiratory depression and lack of established safety.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Initiate at lowest dose (e.g., 50 mg every 6 hours) and titrate cautiously; avoid in patients with renal impairment or concomitant CNS depressants.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
WARNING: RISK OF CARDIAC TOXICITY AND OVERDOSE. Propoxyphene has been withdrawn from the US market due to risk of fatal cardiac arrhythmias (QT prolongation, torsade de pointes) even at therapeutic doses. Use with alcohol or other CNS depressants increases risk of respiratory depression and death.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Cardiac toxicity (QT prolongation, torsade de pointes); respiratory depression; CNS depression (additive with alcohol/other depressants); risk of abuse and dependence; renal or hepatic impairment; elderly patients; history of head injury; increased intracranial pressure; seizure disorders; acute abdominal conditions.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to propoxyphene or opioid cross-sensitivity; known QT prolongation; concurrent use of MAO inhibitors; severe asthma or respiratory depression; obstructive airway disease; paralytic ileus; pregnancy and breastfeeding.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
No specific food interactions; avoid excessive grapefruit juice as it may increase propoxyphene levels.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trimester: Limited data; potential for oligohydramnios. Third trimester: Premature closure of ductus arteriosus, fetal renal dysfunction with oligohydramnios, and neonatal pulmonary hypertension. Avoid in third trimester unless compelling need.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Excreted into breast milk in small amounts; M/P ratio approximately 0.7. Clinical studies show no adverse effects in infants at therapeutic maternal doses. However, due to potential for prostaglandin inhibition, caution is advised, especially in premature infants or those with platelet dysfunction. Consider monitoring infant for bruising, bleeding, or gastrointestinal effects.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No standard dose adjustment recommended for pregnancy. However, due to increased volume of distribution and renal clearance in pregnancy, lower plasma concentrations may occur. Clinical efficacy should guide therapy; dosing at the lower end of the recommended range (e.g., 325 mg every 4-6 hours) is prudent to minimize fetal exposure. Avoid high doses and chronic use in third trimester.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Propoxyphene is a weak opioid analgesic; avoid in patients with suicidal ideation or history of substance abuse due to risk of overdose and cardiac toxicity (QT prolongation). Use with caution in elderly and renal impairment; start at lower doses. Monitor for respiratory depression, especially when combined with CNS depressants.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not increase dose or frequency.,Do not consume alcohol or other CNS depressants.,May cause dizziness or drowsiness; avoid driving until known effect.,Report any signs of allergic reaction or irregular heartbeat.,Do not stop abruptly; withdrawal symptoms may occur.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPHENE 65 vs ACEPHEN, answered by our medical review team.
PROPHENE 65 is a Opioid Analgesic that works by Propoxyphene is a weak opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering perception of pain. It also has local anesthetic and moderate antitussive effects.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPHENE 65 and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPHENE 65 is: Propoxyphene napsylate 100 mg orally every 4 hours as needed for pain; maximum 600 mg/day.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPHENE 65 and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPHENE 65 is classified as Category C. FDA Pregnancy Category C. First trimester: Risk of neural tube defects, cardiovascular malformations, and cleft lip/palate based on prostaglandin synthesis inhibition. Second trime. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.